(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 July 2020 (16.07.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/146535 A1

(51) International Patent Classification:
C07K 16/26 (2006.01)

(21) International Application Number:
PCT/US2020/012790

(22) International Filing Date:
08 January 2020 (08.01.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/789,828	08 January 2019 (08.01.2019)	US
62/840,967	30 April 2019 (30.04.2019)	US
62/841,585	01 May 2019 (01.05.2019)	US
62/872,983	11 July 2019 (11.07.2019)	US

(71) Applicant: **ALDER BIOPHARMACEUTICALS, INC.** [US/US]; 11804 North Creek Parkway South, Bothell, Washington 98011 (US).

(72) Inventors: **CADY, Roger, K.**; c/o ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL, Washington 98011 (US). **SMITH, Jeffrey, T.L.**; 42 ABINGTON, MALAHIDE, DUBLIN, 13 (IE). **HIRMAN, Joseph**; c/o ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL, Washington 98011 (US). **SCHAEFFLER, Barbara**; c/o ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL, Washington 98011 (US).

(74) Agent: **TESKIN, Robin, L.** et al.; BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, PC, Intellectual Property Department, 901 K Street, NW, Suite 900, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES

Figure 1A - Heavy Chain Protein Sequence

Sequence Name	FR1	CDR1	FR2	CDR2
Ab1	QSLEESGGRLVTPGTPLTLTCTVSGLDLS	SYYMQ	WVRQAPGKGLEWIG	VIGINDNTYYASWAKG
Ab2	EVQLVESGGGLVQPGGSLRLSCAVSGLDLS	SYYMQ	WVRQAPGKGLEWVG	VIGINDNTYYASWAKG
Ab3	EVQLVESGGGLVQPGGSLRLSCAVSGLDLS	SYYMQ	WVRQAPGKGLEWVG	VIGINDNTYYASWAKG
Ab4	QSLEESGGRLVTPGTPLTLTCSVSGIDLS	GYYMN	WVRQAPGKGLEWIG	VIGINGATYYASWAKG
Ab5	EVQLVESGGGLVQPGGSLRLSCAVSGIDLS	GYYMN	WVRQAPGKGLEWVG	VIGINGATYYASWAKG
Ab6	EVQLVESGGGLVQPGGSLRLSCAVSGIDLS	GYYMN	WVRQAPGKGLEWVG	VIGINGATYYASWAKG
Ab7	QEQLKESGGRLVTPGTSLTLTCTVSGIDLS	NHYMQ	WVRQAPGKGLEWIG	VVGINGRTYYASWAKG
Ab8	EVQLVESGGGLVQPGGSLRLSCAVSGIDLS	NHYMQ	WVRQAPGKGLEWVG	VVGINGRTYYASWAKG
Ab9	QSLEESGGRLVTPGTPLTLTCTVSGIGLS	SYYMQ	WVRQSPGRGLEWIG	VIGSDGKTYYATWAKG
Ab10	EVQLVESGGGLVQPGGSLRLSCAVSGIGLS	SYYMQ	WVRQAPGKGLEWVG	VIGSDGKTYYATWAKG
Ab11	QSLEESGGRLVTPGGSLTLTCTVSGIDVT	NYYMQ	WVRQAPGKGLEWIG	VIGVNGKRYYASWAKG
Ab12	EVQLVESGGGLVQPGGSLRLSCAVSGIDVT	NYYMQ	WVRQAPGKGLEWVG	VIGVNGKRYYASWAKG
Ab13	QSVEESGGGLVQPEGSLTLTCTASGFDFS	SNAMW	WVRQAPGKGLEWIG	CIYNGDGSTYYASWVNG
Ab14	EVQLVESGGGLVQPGGSLRLSCAVSGIGLS	SYYMQ	WVRQAPGKGLEWVG	VIGSDGKTYYATWAKG

(57) Abstract: Methods for treatment or prevention of medication overuse headache are provided. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

[Continued on next page]

WO 2020/146535 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*